These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 23433435)
1. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. Heukelom J; Hamming O; Bartelink H; Hoebers F; Giralt J; Herlestam T; Verheij M; van den Brekel M; Vogel W; Slevin N; Deutsch E; Sonke JJ; Lambin P; Rasch C BMC Cancer; 2013 Feb; 13():84. PubMed ID: 23433435 [TBL] [Abstract][Full Text] [Related]
2. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer. Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976 [TBL] [Abstract][Full Text] [Related]
3. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654 [TBL] [Abstract][Full Text] [Related]
4. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck. Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383 [TBL] [Abstract][Full Text] [Related]
5. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma. Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959 [TBL] [Abstract][Full Text] [Related]
6. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844 [TBL] [Abstract][Full Text] [Related]
7. Prospective phase II trial of cetuximab plus VMAT-SIB in locally advanced head and neck squamous cell carcinoma. Feasibility and tolerability in elderly and chemotherapy-ineligible patients. Alongi F; Bignardi M; Garassino I; Pentimalli S; Cavina R; Mancosu P; Reggiori G; Poletti A; Ferrari D; Foa P; Bigoni A; Dragonetti A; Salvatori P; Spahiu O; Fogliata A; Cozzi L; Santoro A; Scorsetti M Strahlenther Onkol; 2012 Jan; 188(1):49-55. PubMed ID: 22194030 [TBL] [Abstract][Full Text] [Related]
8. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. Pajares B; Trigo JM; Toledo MD; Álvarez M; González-Hermoso C; Rueda A; Medina JA; de Luque V; Jerez JM; Alba E BMC Cancer; 2013 Jan; 13():26. PubMed ID: 23331666 [TBL] [Abstract][Full Text] [Related]
9. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial. Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE Trials; 2014 Nov; 15():469. PubMed ID: 25432788 [TBL] [Abstract][Full Text] [Related]
10. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol. Pigorsch SU; Wilkens JJ; Kampfer S; Kehl V; Hapfelmeier A; Schläger C; Bier H; Schwaiger M; Combs SE Radiat Oncol; 2017 Mar; 12(1):45. PubMed ID: 28249612 [TBL] [Abstract][Full Text] [Related]
11. A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE). de Leeuw ALMP; Giralt J; Tao Y; Benavente S; France Nguyen TV; Hoebers FJP; Hoeben A; Terhaard CHJ; Wai Lee L; Friesland S; Steenbakkers RJHM; Tans L; Heukelom J; Kayembe MT; van Kranen SR; Bartelink H; Rasch CRN; Sonke JJ; Hamming-Vrieze O Radiother Oncol; 2024 Jul; 196():110281. PubMed ID: 38636708 [TBL] [Abstract][Full Text] [Related]
12. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372 [TBL] [Abstract][Full Text] [Related]
13. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. Ang KK; Zhang Q; Rosenthal DI; Nguyen-Tan PF; Sherman EJ; Weber RS; Galvin JM; Bonner JA; Harris J; El-Naggar AK; Gillison ML; Jordan RC; Konski AA; Thorstad WL; Trotti A; Beitler JJ; Garden AS; Spanos WJ; Yom SS; Axelrod RS J Clin Oncol; 2014 Sep; 32(27):2940-50. PubMed ID: 25154822 [TBL] [Abstract][Full Text] [Related]
14. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity]. Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial. Tao Y; Biau J; Sun XS; Sire C; Martin L; Alfonsi M; Prevost JB; Modesto A; Lafond C; Tourani JM; Miroir J; Kaminsky MC; Coutte A; Liem X; Chautard E; Vauleon E; Drouet F; Ruffier A; Ramee JF; Waksi G; Péchery A; Wanneveich M; Guigay J; Aupérin A; Bourhis J Ann Oncol; 2023 Jan; 34(1):101-110. PubMed ID: 36522816 [TBL] [Abstract][Full Text] [Related]
17. A comparative study of concomitant boost radiation versus concomitant boost with concurrent chemoradiation versus standard fractionation chemoradiation in locally advanced head-and-neck cancer. Gupta P; Dhull AK; Kaushal V J Cancer Res Ther; 2020; 16(3):478-484. PubMed ID: 32719254 [TBL] [Abstract][Full Text] [Related]
18. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Levy AR; Johnston KM; Sambrook J; Donato B; Penrod JR; Corral M; Chasen M Curr Med Res Opin; 2011 Dec; 27(12):2253-9. PubMed ID: 22017232 [TBL] [Abstract][Full Text] [Related]
19. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab. Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704 [TBL] [Abstract][Full Text] [Related]
20. Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial. Suntharalingam M; Winter K; Ilson D; Dicker AP; Kachnic L; Konski A; Chakravarthy AB; Anker CJ; Thakrar H; Horiba N; Dubey A; Greenberger JS; Raben A; Giguere J; Roof K; Videtic G; Pollock J; Safran H; Crane CH JAMA Oncol; 2017 Nov; 3(11):1520-1528. PubMed ID: 28687830 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]